SynerK Biotech Limited (20240376476). NUCLEIC ACID TARGETING PROPROTEIN CONVERTASE SUBTILISIN/KEXIN 9 AND USES THEREOF simplified abstract
Contents
- 1 NUCLEIC ACID TARGETING PROPROTEIN CONVERTASE SUBTILISIN/KEXIN 9 AND USES THEREOF
- 1.1 Organization Name
- 1.2 Inventor(s)
- 1.3 NUCLEIC ACID TARGETING PROPROTEIN CONVERTASE SUBTILISIN/KEXIN 9 AND USES THEREOF - A simplified explanation of the abstract
- 1.4 Potential Applications
- 1.5 Problems Solved
- 1.6 Benefits
- 1.7 Commercial Applications
- 1.8 Prior Art
- 1.9 Frequently Updated Research
- 1.10 Questions about Nucleic Acid Targeting PCSK9
- 1.11 Original Abstract Submitted
NUCLEIC ACID TARGETING PROPROTEIN CONVERTASE SUBTILISIN/KEXIN 9 AND USES THEREOF
Organization Name
Inventor(s)
Weiwen Jiang of Winchester MA (US)
Jimmy Xibai Tang of Hong Kong (HK)
NUCLEIC ACID TARGETING PROPROTEIN CONVERTASE SUBTILISIN/KEXIN 9 AND USES THEREOF - A simplified explanation of the abstract
This abstract first appeared for US patent application 20240376476 titled 'NUCLEIC ACID TARGETING PROPROTEIN CONVERTASE SUBTILISIN/KEXIN 9 AND USES THEREOF
The present disclosure pertains to biotechnology and reveals a nucleic acid targeting proprotein convertase subtilisin/kexin 9 (PCSK9) and its uses. The nucleic acid can effectively inhibit PCSK9 expression, potentially treating and preventing hyperlipidemia-related diseases.
- Nucleic acid targets PCSK9 to inhibit its expression
- Treatment and prevention of hyperlipidemia-related diseases
- Biotechnological innovation with potential therapeutic applications
- Potential for personalized medicine approaches
- Novel approach to addressing lipid metabolism disorders
Potential Applications
The technology can be applied in the development of novel therapeutics for hyperlipidemia-related diseases, potentially improving patient outcomes and quality of life.
Problems Solved
This technology addresses the challenge of effectively targeting PCSK9 to regulate lipid metabolism and treat hyperlipidemia-related conditions.
Benefits
The technology offers a promising avenue for the development of targeted therapies for hyperlipidemia, potentially reducing the burden of cardiovascular diseases and associated complications.
Commercial Applications
"Targeted Nucleic Acid Therapy for Hyperlipidemia: Market Potential and Therapeutic Implications"
Prior Art
Researchers interested in this technology may explore prior studies on PCSK9 inhibition and nucleic acid-based therapies for hyperlipidemia.
Frequently Updated Research
Stay updated on the latest research on PCSK9 inhibition and nucleic acid therapeutics for hyperlipidemia to remain informed about advancements in the field.
Questions about Nucleic Acid Targeting PCSK9
Inhibiting PCSK9 expression can lead to reduced LDL cholesterol levels, potentially lowering the risk of cardiovascular diseases.
How does nucleic acid targeting PCSK9 differ from traditional hyperlipidemia treatments?
Nucleic acid targeting PCSK9 offers a more targeted approach to regulating lipid metabolism compared to traditional pharmacological interventions.
Original Abstract Submitted
the present disclosure relates to the technical field of biotechnology, and discloses a nucleic acid targeting proprotein convertase subtilisin/kexin 9 and uses thereof. the nucleic acid provided by the present disclosure can effectively inhibit the expression of pcsk9, thereby being capable of treating and/or preventing hyperlipidemia related diseases.
